|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
Antibiotic resistance threatens to return us to the pre-antibiotic era. Several initiatives, including public-private partnerships and government incentives have resulted in a remarkable upturn of new antibiotic approved in the last 3 years. This activity will examine antibiotics approved during this period, their spectrum of activity, data supporting use and potential place in therapy as well as important new indications for some important antibiotics. In addition, the successful incentives leading to new antibiotics will be reviewed along with trial designs for antibiotics aimed at priority pathogens. Finally, a glimpse into antibiotics in phase 3 trials will provide a brief review of drugs by spectrum and indications under study.
The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:
- Describe new antibiotics approved in 2018 and 2019, the indications they are approved for and the priority pathogens they target.
- Discuss the FDA definitions for evaluation of new antibiotics for SSTI, cUTI and cIAI.
- List important antibiotics in late stage development and their potential role if approved.
Kelly Echevarria, PharmD, BCPS, AQ-ID, BCIDP
National Clinical Pharmacy Program Manager, Infectious Diseases
VHA Pharmacy Benefits Management
Clinical Assistant Professor
University of Texas Health Science Center in San Antonio
University of Texas College of Pharmacy
Release Date: 07-25-2019
Expiration Date: 07-25-2022
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-275-H01-P has been assigned to this home study knowledge-based activity (initial release date 7-25-2019). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Echevarria has no relevant commercial or financial relationships to disclose.
This activity is provided by ProCE, Inc. and SIDP.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
LIVE Webinar Attendance (Enter Event/Attendance Code provided during webinar to verify attendance)
|Date||7/25/2019 3:00:00 PM|